DOI: 10.4244/EIJV9I1A24

“First-in-man” use of bioresorbable vascular scaffold in saphenous vein graft

Paul Jau Lueng Ong, MD, FESC; Fahim Haider Jafary, MD, FACC; Hee Hwa Ho*, MD, FACC

A 52-year-old male underwent coronary angiography for non-ST-elevation myocardial infarction. He had a known history of diabetes mellitus and also triple vessel disease with prior coronary artery bypass grafting (CABG) six years ago. Angiography showed total occlusion of the left anterior descending (LAD), circumflex and right coronary arteries (RCA). Left internal mammary graft to LAD was patent. However, there were two critical stenoses in the mid-body of the SVG-RCA and SVG-obtuse marginal (OM) grafts (Figure 1A and Figure 1B). We proceeded to perform percutaneous coronary intervention of both lesions with the prophylactic use of an embolic protection device. After predilation of both lesions, an Absorb™ bioresorbable vascular scaffold 3.0×18 mm (Abbott Vascular, Santa Clara, CA, USA) was implanted in the mid-body of the saphenous vein graft (SVG)-RCA (Figure 1C) whereas a XIENCE PRIME™ 3.0×23 mm stent (Abbott Vascular) was implanted in the mid-body of the SVG-OM (Figure 1D). The final angiographic results were good and there was no in-lab complication. He presented three months later with atypical chest pain and underwent cardiac computed tomographic angiography (CCTA). Both bioresorbable vascular scaffold (BVS) and XIENCE PRIME stent were widely patent on CCTA (Figure 1E and Figure 1F). No blooming artefact was observed within the treated SVG-RCA segment with the BVS platinum markers clearly seen on CCTA.

Figure 1. A) Baseline angiography showing critical stenosis in mid-body of SVG-RCA. B) Baseline angiography showing critical stenosis in mid-body of SVG-OM. C) Final angiography of SVG-RCA (after successful deployment of Absorb). D) Final angiography of SVG-OM (after successful deployment of XIENCE stent). E) CCTA showing widely patent BVS in mid-body of SVG-RCA. No blooming artefact observed with the BVS platinum markers clearly seen (small arrowheads >>) on CCTA. F) CCTA showing widely patent XIENCE metallic stent in mid-body of SVG-OM.

Conflict of interest statement

The authors have no conflicts of interest to declare.

Online data supplement

Moving image 1. Movie clip showing the appearance of BVS in the mid-body of the SVG-RCA on CCTA.

Moving image 2. Movie clip showing the appearance of XIENCE stent in the mid-body of the SVG-OM on CCTA.

Supplementary data

To read the full content of this article, please download the PDF.

Moving image 1.
Moving image 2.
Volume 9 Number 1
May 21, 2013
Volume 9 Number 1
View full issue


Key metrics

Suggested by Cory

IMAGE IN CARDIOLOGY

10.4244/EIJV11I1A14 May 19, 2015
Very late bioresorbable vascular scaffold thrombosis: a new clinical entity
Azzalini L et al
free

IMAGE IN CARDIOLOGY

10.4244/EIJV10I12A253 Apr 20, 2015
Coronary perforation after bioresorbable vascular scaffold implantation
Gomez-Lara J et al
free

CLINICAL RESEARCH

10.4244/EIJ-D-17-00246 Jul 20, 2017
One-year clinical results of the Italian diffuse/multivessel disease ABSORB prospective registry (IT-DISAPPEARS)
Testa L et al
free
Trending articles
334.7

State-of-the-Art Review

10.4244/EIJ-D-21-00904 Apr 1, 2022
Antiplatelet therapy after percutaneous coronary intervention
Angiolillo D et al
free
84.05

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
45.25

State-of-the-Art

10.4244/EIJ-D-25-01346 May 4, 2026
Slow flow and no reflow after percutaneous coronary intervention
Brugaletta S et al
free
42.15

State-of-the-Art

10.4244/EIJ-D-25-00896 Apr 6, 2026
Pretreatment with antiplatelet agents in patients undergoing coronary revascularisation
Kaur G et al
free
38.2

State-of-the-Art

10.4244/EIJ-D-24-00195 Apr 7, 2025
Percutaneous coronary intervention for calcified and resistant lesions
Pesarini G et al
free
33.5

Original Research

10.4244/EIJ-D-26-00032 May 15, 2026
Glucocorticoids to reduce permanent pacemaker implantation after TAVI: the GLUCO-TAVI randomised trial
Fuertes-Kenneally L et al
32.2

State-of-the-Art

10.4244/EIJ-D-25-00874 Jun 1, 2026
TAVI and coronary interventions: indications, technical considerations, and clinical scenarios
Aquino Bruno H et al
free
29.2

Original Research

10.4244/EIJ-D-25-01370 May 21, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al
29.2

Original Research

10.4244/EIJ-D-25-01370 Jun 1, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al
X

PCR
Impact factor: 9.2
2025 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2026)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2026 Europa Group - All rights reserved